Skull Base & Orbit

Skull Base Survival Tools: Map the Spread Through Foramina

Fellowship-level neuroradiology teaching by E. Brooke Schrickel, MD. Open this topic in the interactive reading room →

Watch · concise explainerVisual summary

Core clinical idea

At the skull base your job is usually staging extent and mapping spread through foramina, not naming a single entity. The one reflex that catches the subtle case: on every midline sagittal MR, the clivus must contain bright T1 fatty marrow — if it's dark, there's a problem until proven otherwise. That look, plus pre-contrast T1, CT+MR together, and the pterygopalatine-fossa map, is the whole survival kit.

Bottom line

At the skull base you stage and map, not just name — check the clival marrow on every sagittal, demand pre-contrast T1 and CT+MR, and trace spread through the pterygopalatine fossa and the foramina.

Core workstation questions

Does the clivus have bright fatty marrow on the midline sagittal — and do I have a pre-contrast T1 to judge it?
Do I have both CT and MR — bone/foramina pattern and marrow/soft-tissue extent?
Is this near the pterygopalatine fossa, and have I checked every spoke (nasal, nasopharynx, masticator, foramen rotundum, vidian, inferior orbital fissure, palatine foramina)?
Is this a marrow-replacing lesion where I must name lymphoma, metastasis, and myeloma together?
Is this arising in the skull base, from above, or from below — and have I mapped the route of spread?
Is this clival/petroclival lesion midline (favor chordoma) or off-midline (favor chondrosarcoma)?
For a T2-bright petrous apex lesion, is it T1-bright and nonenhancing (cholesterol granuloma) or enhancing (chondrosarcoma)?
Before calling a jugular foramen mass, have I excluded flow artifact, a high/diverticular bulb, and thrombosis with MRV?

What changes reporting / management

When you can't name it, still stage it — extent determines prognosis, surgical approach, and therapy.
Report which pterygopalatine-fossa spokes are involved; that map is the staging.
For marrow-replacing lesions, name lymphoma, metastasis, and myeloma in the same breath.
Demand pre-contrast T1 (and fat-suppressed post-contrast) so marrow replacement isn't masked by enhancement/fat.
Use multiplanar CT with MR to read how disease traverses the foramina.
State midline vs paramedian for clival/petroclival lesions — it most shifts the chordoma-vs-chondrosarcoma call.
Work the jugular-foramen mimic checklist (artifact, high/diverticular bulb, thrombosis) before naming a tumor.
Raise any possible vascular lesion (including dural AVF/AVM) and recommend CTA/MRA before surgery; recognize juvenile angiofibroma as a do-not-biopsy lesion.
For a pediatric midline nasal mass, recommend MRI to exclude a cephalocele/intracranial connection and define cephalocele content before ENT operates.
For a destructive sellar mass, check whether the carotids are narrowed and whether it's inseparable from the gland before discarding macroadenoma.

Practical traps

Reading the skull base without a pre-contrast T1 — enhancing tumor and normal marrow fat both look bright.
Missing a perineural/foraminal route of spread off the pterygopalatine fossa.
Trying to distinguish lymphoma from metastasis from myeloma when they're indistinguishable — name all three.
Overlooking NPC creeping superolaterally through the sinus of Morgagni (pharyngobasilar fascia gap).
Letting the bony-anatomy tour become a memorization dump instead of the functional spread-conduits.
Calling a T2-bright petrous apex lesion a cholesterol granuloma when chondrosarcoma mimics it (granuloma is T1-bright and nonenhancing; chondrosarcoma enhances).
Diagnosing a jugular foramen mass before excluding flow artifact, a high/diverticular bulb, and thrombosis.
Letting a surgeon operate on a vascular lesion mistaken for tumor; biopsying a juvenile angiofibroma.
Sending a child's nasal mass to surgery without an MR to exclude a cephalocele — risking CSF leak, infection, brain injury.
Excluding macroadenoma just because a sellar mass is destructive — adenomas classically don't narrow the carotids.

Teaching pearls

Look at the clival marrow on every midline sagittal — it has to have fat; dark is a problem.
No pre-contrast T1, no skull-base read — enhancing tumor and normal fat both look bright.
CT and MR are complementary here — you often need both to narrow the differential.
The pterygopalatine fossa is the crossroads — map every spoke for spread.
A marrow-replacing skull-base lesion means saying lymphoma, metastasis, and myeloma in the same breath.
Midline at the clivus favors chordoma; off-midline at the petroclival fissure favors chondrosarcoma.
T2-bright petrous apex: cholesterol granuloma is T1-bright and nonenhancing; chondrosarcoma enhances — get both modalities.
Before calling a jugular foramen mass, exclude flow artifact, a high/diverticular bulb, and thrombosis.
If a skull-base lesion could be vascular, say so and get CTA/MRA — don't let the surgeon create red.
A child's nasal mass needs an MR to exclude a cephalocele before ENT operates.

Teaching visuals

Skull base divide-and-conquer foramina map

Source lectures

Skull Base: Crossroad of Disease, Part 1
Skull Base: Crossroad of Disease, Part 2
Skull Base: Crossroad of Disease, Part 3
Skull Base Anatomy & Pathology – Survival Tools

Educational material for radiology residents and neuroradiology fellows. Nothing here drives individual patient care, and it contains no patient data.